This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
Company News for Nov 25, 2025
by Zacks Equity Research
Companies In The News Are: CVAC, CAAP, NVO, BABA.
airlines biotechnology internet-content pharmaceuticals
The Zacks Analyst Blog Highlights LLY, EPHE, BBC, HELX, XHS and SURI
by Zacks Equity Research
LLY, EPHE, BBC, HELX, XHS and SURI headline last week's top-performing ETFs as healthcare and biotech outperform a weak broader market.
pharmaceuticals
Top Stock Reports for Alphabet, Roche & RTX
by Mark Vickery
Alphabet gains momentum as AI-driven growth in Cloud, Search and YouTube fuels rising customer adoption and revenue strength.
aerospace computers finance industrial-products pharmaceuticals
BAYRYs Cardiovascular Drug Hits Goals in Late-Stage Study
by Zacks Equity Research
Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major bleeding.
biotechnology medical pharmaceuticals
FDA Approves MRK's Keytruda & Keytruda SC Combo in Bladder Cancer
by Zacks Equity Research
Merck gains FDA nod for Keytruda and Keytruda Qlex with Padcev in MIBC, marking the first PD-1 inhibitor plus ADC regimens for this patient group.
pharmaceuticals
Will NVO's U.S. Price Cuts Boost Access & Revive Semaglutide Demand?
by Ahan Chakraborty
Novo Nordisk cuts self-pay prices for Wegovy and Ozempic in the United States, aiming to expand access and counter falling demand.
biotechnology biotechs medical pharmaceuticals
Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally
by Sundeep Ganoria
LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across its portfolio.
biotechs medical pharmaceuticals
Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in
by Sanghamitra Saha
Lilly's $1T valuation and soaring GLP-1 demand spotlight ETFs like IHE, PPH, MEDI, OZEM, MEDX and THNR for investors riding the weight-loss drug boom.
etfs pharmaceuticals
Top Research Reports for JPMorgan Chase, Netflix & AbbVie
by Mark Vickery
JPMorgan's year-to-date gains, NII growth outlook and investment banking pipeline headline today's standout Zacks research picks.
consumer-discretionary finance pharmaceuticals
Healthcare ETFs to Buy as Big Pharma Rapidly Integrates AI
by Aparajita Dutta
LLY's expanding AI alliances highlight how pharma-tech partnerships are transforming healthcare and lifting key sector ETFs like XLV.
etfs pharmaceuticals